Abstract:The binding of drugs to plasma proteins determines its fate within the physiological system, hence profound understanding of its interaction within the bloodstream is important to understand its pharmacodynamics and pharmacokinetics and thereby its therapeutic potential. In this regard, our work delineates the mechanism of interaction of Selumetinib (SEL), a potent anti‐cancer drug showing excellent effect against multiple solid tumors, with plasma protein bovine serum albumin (BSA), using methods such as absorption, steady‐state fluorescence, time‐resolved, fluorescence resonance energy transfer, Fourier transform infrared spectra (FTIR), circular dichroism (CD), synchronous and 3D‐fluorescence, salt fluorescence, molecular docking and molecular dynamic simulations. The BSA fluorescence intensity was quenched with increasing concentration of SEL which indicates interactions of SEL with BSA. Stern–Volmer quenching analysis and lifetime studies indicate the involvement of dynamic quenching. However, some contributions from the static quenching mechanism could not be ruled out unambiguously. The association constant was found to be 5.34 × 105 M−1 and it has a single binding site. The Förster distance (r) indicated probable energy transmission between the BSA and SEL. The positive entropy changes and enthalpy change indicate that the main interacting forces are hydrophobic forces, also evidenced by the results of molecular modeling studies. Conformation change in protein framework was revealed from FTIR, synchronous and 3D fluorescence and CD studies. Competitive binding experiments as well as docking studies suggest that SEL attaches itself to site I (subdomain IIA) of BSA where warfarin binds. Molecular dynamic simulations indicate the stability of the SEL–BSA complex. The association energy between BSA and SEL is affected in the presence of different metals differently.

Investigation On The Site-Selective Binding Of Bovine Serum Albumin By Erlotinib Hydrochloride

Evaluation of Molecular Binding Modes on Site Ii of Human Serum Albumin

Spectroscopic and Molecular Docking Studies of Binding Interaction of Gefitinib, Lapatinib and Sunitinib with Bovine Serum Albumin (BSA).

Exploring the binding characteristics of bovine serum albumin with tyrosine Kinase inhibitor Entrectinib: Multi-spectral Analysis and theoretical calculation

Binding Interaction of Sorafenib with Bovine Serum Albumin: Spectroscopic Methodologies and Molecular Docking.

Combined Spectroscopies and Molecular Docking Approach to Characterizing the Binding Interaction of Enalapril with Bovine Serum Albumin.

Exploring the interaction of a potent anti‐cancer drug Selumetinib with bovine serum albumin: Spectral and computational attributes

In vitro study on binding interaction of quinapril with bovine serum albumin (BSA) using multi-spectroscopic and molecular docking methods.

Spectroscopic Studies on the Interaction Between an Anticancer Drug Ampelopsin and Bovine Serum Albumin

Interaction Characterization of a Tyrosine Kinase Inhibitor Erlotinib with a Model Transport Protein in the Presence of Quercetin: A Drug–Protein and Drug–Drug Interaction Investigation Using Multi-Spectroscopic and Computational Approaches

A Biophysical Study of Molecular Interaction of Tucatinib with Bovine Serum Albumin

Study on the binding of novel antitumor drug Ethaselen to bovine serum albumin

Probing into the binding interaction between medroxyprogesterone acetate and bovine serum albumin (BSA): spectroscopic and molecular docking methods.

In vitro study on the binding of gemcitabine to bovine serum albumin.

Thermochemistry Study on Interaction Between Anti-tumor Drug Tegafur and Bovine Serum Albumin

Evaluation of the interaction of novel tyrosine kinase inhibitor apatinib mesylate with bovine serum albumin using spectroscopies and theoretical calculation approaches

Multispectroscopic, electrochemical and molecular docking approaches on binding comparison of camptothecin, 10-hydroxycamptothecin to bovine serum albumin

Spectroscopic Study on the Interaction of Bovine Serum Albumin with Zinc(ii) Phthalocyanine.

Experimental and computational investigation on the binding of anticancer drug gemcitabine with bovine serum albumin

Characterization of Interaction Between Raltitrexed and Bovine Serum Albumin by Optical Spectroscopic Techniques

Evaluation of the binding behavior of olmutinib (HM61713) with model transport protein: Insights from spectroscopic and molecular docking studies